[go: up one dir, main page]

DK3841101T3 - Fremgangsmåde til fremstilling af 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridin - Google Patents

Fremgangsmåde til fremstilling af 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridin Download PDF

Info

Publication number
DK3841101T3
DK3841101T3 DK19759528.3T DK19759528T DK3841101T3 DK 3841101 T3 DK3841101 T3 DK 3841101T3 DK 19759528 T DK19759528 T DK 19759528T DK 3841101 T3 DK3841101 T3 DK 3841101T3
Authority
DK
Denmark
Prior art keywords
pyrazol
methylmorpholin
naphthyridine
methyl
preparation
Prior art date
Application number
DK19759528.3T
Other languages
English (en)
Inventor
Johannes Platzek
Philipp Rubenbauer
Der Haas Hendricus Nicolaas Sebastiaan Van
Sonja Elisabeth Hoogeveen
Oers Matthijs Cornelis Maria Van
Reinerus Gerardus Gieling
Jeroen Alexander Dekker
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63405064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3841101(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Application granted granted Critical
Publication of DK3841101T3 publication Critical patent/DK3841101T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK19759528.3T 2018-08-24 2019-08-22 Fremgangsmåde til fremstilling af 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridin DK3841101T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18190731 2018-08-24
PCT/EP2019/072467 WO2020039025A1 (en) 2018-08-24 2019-08-22 Method for preparing 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine

Publications (1)

Publication Number Publication Date
DK3841101T3 true DK3841101T3 (da) 2023-07-31

Family

ID=63405064

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19759528.3T DK3841101T3 (da) 2018-08-24 2019-08-22 Fremgangsmåde til fremstilling af 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridin

Country Status (28)

Country Link
US (1) US12258343B2 (da)
EP (1) EP3841101B1 (da)
JP (1) JP7422741B2 (da)
KR (1) KR102797099B1 (da)
CN (1) CN112823158B (da)
AU (1) AU2019324521B9 (da)
BR (1) BR112021001309A2 (da)
CA (1) CA3110394A1 (da)
CL (1) CL2021000454A1 (da)
CO (1) CO2021001892A2 (da)
DK (1) DK3841101T3 (da)
ES (1) ES2950825T3 (da)
FI (1) FI3841101T3 (da)
HR (1) HRP20230611T1 (da)
HU (1) HUE062332T2 (da)
IL (1) IL280878A (da)
JO (1) JOP20210032A1 (da)
LT (1) LT3841101T (da)
MX (1) MX2021002132A (da)
MY (1) MY201874A (da)
PE (1) PE20210862A1 (da)
PL (1) PL3841101T3 (da)
PT (1) PT3841101T (da)
RS (1) RS64362B1 (da)
SG (1) SG11202101011RA (da)
SI (1) SI3841101T1 (da)
UA (1) UA128407C2 (da)
WO (1) WO2020039025A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
WO2019025440A1 (en) 2017-08-04 2019-02-07 Bayer Pharma Aktiengesellschaft COMBINATION OF ATR KINASE INHIBITORS AND PD-1 / PD-L1 INHIBITORS
US11236070B2 (en) 2019-05-16 2022-02-01 Novartis Ag Chemical process

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645583A1 (en) * 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
JP2010529031A (ja) * 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
MX2011002367A (es) * 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
CA2872979C (en) * 2011-05-19 2020-02-18 Joaquin Pastor Fernandez Macrocyclic compounds as protein kinase inhibitors
KR101366368B1 (ko) * 2011-07-08 2014-02-21 주식회사 두산 신규 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
WO2018153970A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine

Also Published As

Publication number Publication date
JOP20210032A1 (ar) 2021-02-23
CO2021001892A2 (es) 2021-03-08
AU2019324521B2 (en) 2024-10-31
HUE062332T2 (hu) 2023-10-28
FI3841101T3 (fi) 2023-07-28
CN112823158A (zh) 2021-05-18
JP7422741B2 (ja) 2024-01-26
CA3110394A1 (en) 2020-02-27
UA128407C2 (uk) 2024-07-03
HRP20230611T1 (hr) 2023-09-15
CL2021000454A1 (es) 2021-07-09
PL3841101T3 (pl) 2023-08-21
EP3841101B1 (en) 2023-05-03
MY201874A (en) 2024-03-21
KR20210049845A (ko) 2021-05-06
AU2019324521B9 (en) 2024-11-14
LT3841101T (lt) 2023-06-26
IL280878A (en) 2021-04-29
PT3841101T (pt) 2023-07-25
ES2950825T3 (es) 2023-10-13
BR112021001309A2 (pt) 2021-04-27
CN112823158B (zh) 2023-08-15
US20210253573A1 (en) 2021-08-19
MX2021002132A (es) 2021-04-28
EP3841101A1 (en) 2021-06-30
WO2020039025A1 (en) 2020-02-27
JP2021535122A (ja) 2021-12-16
SG11202101011RA (en) 2021-02-25
SI3841101T1 (sl) 2023-07-31
RS64362B1 (sr) 2023-08-31
PE20210862A1 (es) 2021-05-18
US12258343B2 (en) 2025-03-25
AU2019324521A1 (en) 2021-03-11
KR102797099B1 (ko) 2025-04-18

Similar Documents

Publication Publication Date Title
DK3653617T3 (da) Fremgangsmåde til fremstillingen af (s)-nikotin fra myosmin
DK3303348T3 (da) Naphthyridinforbindelser som JAK-kinaseinhibitorer
MA51771A (fr) Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
DK3433253T3 (da) Pyrimidinforbindelse som JAK-kinase-inhibitorer
DK3468734T3 (da) Elektrodegrafitfræser såvel som fræser til bearbejdelse af oxidkeramikker
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
DK3290418T3 (da) Janus Kinase (JAK)-hæmmere
EP3376865A4 (en) 4 - ((6- (2,4-difluorophenyl) -1,1-difluoro-2-HYDROXY-3- (1 H
DK3331891T3 (da) Fremgangsmåde til fremstilling af en i det væsentlige diastereomert ren phosphorodiamidat-oligomer, phosphorodiamidat-oligomer fremstillet ved hjælp af en sådan fremgangsmåde og farmaceutisk sammensætning, der omfatter en sådan phosphoroamidat-oligomer
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3752283T3 (da) Overlegen kerne-i-skal-komponent-kompositadsorbenter til vsavpsapsa-systemer
DK3841101T3 (da) Fremgangsmåde til fremstilling af 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridin
DK3227273T3 (da) Sammensætninger, som omfatter 2-((1-(2(4-fluorphenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-on, til behanlding af skizofreni
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3458467T3 (da) Fremgangsmåde til 6,7-alfa-epoxidering af steroid-4,6-diener
PL3976589T3 (pl) Sposoby wytwarzania kwasu 5-bromo-2-(3-chloropirydyn-2-ylo)-2H-pirazolo-3-karboksylowego
DK3339387T3 (da) Forbindelser på basis af addukter med isocyanater til belægningssammensætninger
DK3830243T3 (da) Fremgangsmåde til fremstilling af personlige blodkar
EP3541794A4 (en) 4 - ((6- (2- (2,4-DIFLUOROPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL) PROPYL) PYRIDIN-3-YL) OXY) BENZONITRILE AND METHOD FOR THE PRODUCTION THEREOF
DK3507282T3 (da) Fremgangsmåde til fremstilling af indolcarboxamidforbindelser
DK3431590T3 (da) Fremgangsmåde til fremstilling af aktiveret hepatocytvækstfaktor (hgf)
DK3599243T3 (da) 17beta-heterocyklyl-digitalis-lignende forbindelser til behandlingen af hjertesvigt
DK3423440T3 (da) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-on-derivat til behandlingen af hjernetumorer
DK3356329T3 (da) Fremgangsmåde til fremstilling af 1-(4-methansulfonyl-2-trifluormethylbenzyl)-2-methyl-1H-pyrrolo[2,3-B]pyridin-3-yleddikesyre